Knights of Columbus Asset Advisors LLC trimmed its stake in shares of Bioventus Inc. (NASDAQ:BVS – Free Report) by 44.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 161,657 shares of the company’s stock after selling 128,688 shares during the quarter. Knights of Columbus Asset Advisors LLC owned about 0.19% of Bioventus worth $2,203,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BVS. Signaturefd LLC raised its position in shares of Bioventus by 2,809.1% in the third quarter. Signaturefd LLC now owns 1,920 shares of the company’s stock valued at $26,000 after purchasing an additional 1,854 shares during the period. USA Financial Formulas bought a new stake in shares of Bioventus during the 3rd quarter worth about $42,000. Covestor Ltd boosted its holdings in shares of Bioventus by 25.6% during the 3rd quarter. Covestor Ltd now owns 5,808 shares of the company’s stock worth $79,000 after buying an additional 1,182 shares during the period. Quantum Financial Partners LLC boosted its holdings in shares of Bioventus by 11.8% during the 3rd quarter. Quantum Financial Partners LLC now owns 14,200 shares of the company’s stock worth $194,000 after buying an additional 1,500 shares during the period. Finally, State of Alaska Department of Revenue boosted its holdings in shares of Bioventus by 446.4% during the 3rd quarter. State of Alaska Department of Revenue now owns 18,953 shares of the company’s stock worth $258,000 after buying an additional 15,484 shares during the period. 62.94% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
BVS has been the topic of several research analyst reports. Wall Street Zen cut shares of Bioventus from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 7th. Weiss Ratings downgraded Bioventus from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, November 4th. Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 target price on shares of Bioventus in a research report on Monday, August 17th. Craig Hallum restated a “buy” rating and issued a $18.00 price target on shares of Bioventus in a research note on Thursday, August 6th. Finally, Barrington Research set a $18.00 price target on shares of Bioventus in a research report on Thursday, August 6th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.60.
Bioventus Trading Down 1.7%
Shares of NASDAQ:BVS opened at $10.99 on Thursday. The business’s 50 day simple moving average is $13.28 and its 200 day simple moving average is $11.01. Bioventus Inc. has a 1 year low of $6.47 and a 1 year high of $15.89. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.68 and a quick ratio of 1.16. The company has a market capitalization of $926.02 million, a P/E ratio of 14.33, a P/E/G ratio of 1.43 and a beta of 0.66.
Bioventus (NASDAQ:BVS – Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The company reported $0.17 earnings per share for the quarter, meeting the consensus estimate of $0.17. The firm had revenue of $142.44 million during the quarter. Bioventus had a return on equity of 26.31% and a net margin of 9.78%. On average, research analysts anticipate that Bioventus Inc. will post 0.78 EPS for the current fiscal year.
Bioventus Company Profile
Bioventus Inc. is a medical technology company focused on helping patients recover from musculoskeletal conditions and injuries. Its products and services support bone healing, pain management and surgical care. The company’s offerings include noninvasive devices that use ultrasound to support bone healing, injectable treatments for osteoarthritis pain, and surgical products such as bone graft materials and ultrasonic instruments used in procedures. Bioventus began operations in 2012, originating from businesses previously owned by Smith & Nephew.
Featured Stories
- Five stocks we like better than Bioventus
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
